1-3 of 3
Kibum Kim
Close
Sort by
Journal Articles

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Yu-Hua Fu, Shang-Ju Wu, Elise Chia-Hui Tan, Chi-Chuan Wang, Kibum Kim, Wen-Chien Chou, Fang-Ju Lin
Journal: Blood
Blood (2022) 140 (Supplement 1): 10808–10809.
https://doi.org/10.1182/blood-2022-162980
Published: 2022
Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Anthea Peters, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Dan Huang, Eva E. Waltl, Mark Winderlich, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 183.
https://doi.org/10.1182/blood-2021-148302
Published: 2021
Journal Articles

Cost-Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Patients with Chronic Myeloid Leukemia

Kibum Kim, PhD, Gwendolyn A. McMillin, PhD, Philip S. Bernard, MD, Srinivas K. Tantravahi, MBBS, Brandon Walker, MS, Robert L Schmidt, MD PhD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 3547.
https://doi.org/10.1182/blood-2018-99-120263
Published: 2018